Description

Menopur® contains a medicine called menotrophin. Menopur® is used in cases of infertility to help follicles mature in the ovaries. It also helps multiple follicles to develop during assisted reproduction, so the eggs can be collected and fertilised outside of the body.

Menopur® is also used to treat males with poor sperm count.

What is Menopur® and How does it Work?

In women, Menopur® is used for:
• Infertility caused by eggs not being produced properly in the ovaries (anovulatory infertility and polycystic ovarian disease). It works by helping follicles (which contain eggs) to mature in the ovaries.
• It works by helping multiple follicles and eggs to develop. The eggs are then harvested and fertilised outside the body.
In men, Menopur® is used for:
• Low sperm count (oligospermia).

Selling/Dispensing Pack size:

Per Multi-Dose Vial (Can only be purchased with orders being delivered within the UK)

Ingredients:

Active ingredient
Each vial of lyophilised product contains highly purified menotrophin (human menopausal gonadotrophin, HMG) corresponding to 1200IU human follicle-stimulating hormone (FSH) and 1200IU human luteinising hormone (LH) activity.
Human Chorionic Gonadotrophin (hCG), a naturally occurring hormone in postmenopausal urine, is present in Menopur® and contributes to the overall luteinizing hormone activity.

Usage Directions and Storage:

Keep out of the reach and sight of children.
Prior to reconstitution, store in a refrigerator at 2°C – 8°C. Do not freeze. Keep in the original container in order to protect from light.
After reconstitution, the solution may be stored for a maximum of 28 days at room temperature, not more than 25°C. Do not freeze.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Warnings and Side Effects:

The most frequently reported side effects during treatment with Menopur® in clinical trials are ovarian hyperstimulation, abdominal pain, headache, enlarged abdomen, inflammation at the injection site, pain at the injection site and nausea, with an incidence rate between 2% and 7%.